Imatinib (IMA) is a BCR-ABL tyrosine kinase inhibitor (TKI) that is highly sensitive in patients with newly diagnosed CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.